CAR-TCR Summit Europe

CARTCR EuropeThe CAR-TCR Summit Europe (London, 20-22 February) is the leading end-to-end summit focused on the global delivery of safe, effective and commercially successful CAR and TCR cell immunotherapies. It brings you access to the leaders in this field and the hub of companies creating novel innovations in Europe. It is your opportunity to network, interact and learn as the stage is set for visionary leaders to transform the commercial and clinical delivery of cancer therapeutics with CAR-T and TCR therapies. You can gain exclusive insight on current clinical programs and case studies on the wave of next generation CAR-TCR candidates from those pioneering in this field.

Here is a quick summary of what’s new for this year’s meeting:

Solid tumours: Hear about the novel innovations being implemented to drive the killing potential of CAR-TCR therapies in solid tumour indications with Leucid Bio and T-Knife.

Safety: Ensure adverse events and toxic side effects are overcome to guarantee the safety profiles of these life-changing therapies, and ensure accessibility to broader patient populations with Pfizer and Celgene.

Manufacturing: Miltenyi Biotec highlight the most important aspects of manufacturing scale up alongside automation innovation to reduce COGs.

Regulations: With Yescarta and Kymriah still pending EMA approval, the first to market in Europe will be another huge milestone for this industry. Learn how to navigate the regulatory minefield to ensure successful market approval of your therapeutic with the Chair of the CAT.

Commercialisation: Hear from Kite Pharma and their initial commercial experience in the field.

Lessons learned: Clinical development lessons from Novartis and Adaptimmune with their advanced programmes.

For more information, please visit:



20-22 February 2018




Hanson Wade